This content is machine translated Diabetes mellitus Treatment of comorbidities in older people One in five people over 65 and one in four people over 75 are affected by diabetes. Global projections predict a 2.5-fold increase in diabetes prevalence over the next 25...… CME-Test
View Post 5 min This content is machine translated Journal Club Nephrolithiasis and gout: SGLT2i could be an effective supplement Nephrolithiasis and gout are diseases with an increasing global burden and often co-occur with type 2 diabetes mellitus. SGLT2 inhibitors, which were first approved for the treatment of hyperglycemia in…
View Post 3 min This content is machine translated Real-world data from tirzepatide Safety comparable to other GLP1-RA As more people with type 2 diabetes (T2D) take medication to control blood sugar levels and lose weight, safety concerns have arisen. Real-world evidence from the US Food and Drug…
View Post 4 min This content is machine translated Pharmacotherapy for people over 80 A case of age discrimination? SGLT2 inhibitors and GLP1 receptor agonists have emerged as the drugs of first choice in the guidelines for type 2 diabetes. Sulfonylureas and insulin, on the other hand, were deprioritized…
View Post 5 min This content is machine translated Diabetic neuropathy and retinopathy How risky are SGLT2i and GLP1-RA? Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1-RA) play an important role in diabetes therapy. However, their effect on diabetic neuropathy and retinopathy is not clear.…
View Post 4 min This content is machine translated Renal effects of empagliflozin Combination with semaglutide does not reduce albuminuria more than Empa mono SGLT2 inhibitors and GLP1 receptor agonists (GLP1-RA) are antidiabetic drugs with the potential to preserve kidney function. Their different mechanisms of action suggest that combination therapy could have additive or…
